Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To study the length of grace period used to define use of oral anticoagulants has a differential impact on the incidence rates of major bleeding associated with warfarin and DOACs

Next Previous
Trial Profile

To study the length of grace period used to define use of oral anticoagulants has a differential impact on the incidence rates of major bleeding associated with warfarin and DOACs

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use

Most Recent Events

  • 05 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top